Treatment in the Elderly

C 2017

Treatment in the Elderly

SZTURZ, Petr a Jan B. VERMORKEN

Základní údaje

Originální název

Treatment in the Elderly

Autoři

SZTURZ, Petr (203 Česká republika, garant, domácí) a Jan B. VERMORKEN (56 Belgie)

Vydání

Switzerland, Critical Issues in Head and Neck Oncology, od s. 251-261, 11 s. 2017

Nakladatel

Springer International Publishing

Další údaje

Jazyk

angličtina

Typ výsledku

Kapitola resp. kapitoly v odborné knize

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Forma vydání

tištěná verze "print"

Kód RIV

RIV/00216224:14110/17:00096007

Organizační jednotka

Lékařská fakulta

ISBN

978-3-319-42907-6

DOI

http://dx.doi.org/10.1007/978-3-319-42909-0_16

Klíčová slova anglicky

Biological age; Comorbidities; Functional status; Comprehensive geriatric assessment; Screening; Chemotherapy; Epidermal growth factor receptor inhibitor

Štítky

EL OK, topvydavatel

Změněno: 11. 1. 2017 12:54, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Older age is the major risk factor for cancer development and the steadily rising global cancer burden is directly linked to the growing number of the elderly population. In the United States, the proportion of squamous cell carcinoma of the head and neck (SCCHN) patients over 65 is estimated to increase from 54 % in 2010 up to 66 % by 2030. However, chronological age does not always correlate with biological parameters to reliably predict life expectancy, functional reserve and the risk of treatment side effects in an individual. Thus, geriatric assessment tools were developed to differentiate between the fit and frail senior persons and guide treatment decisions. According to the recommended two-step approach, geriatric screening tests (e.g. G8 or Flemish version of the Triage Risk Screening Tool) are used to select patients further requiring a full evaluation. A comprehensive geriatric assessment, which is otherwise time-consuming and not necessary in every case, evaluates functional status, comorbidities, medications, cognition, psychological status, nutrition and social support. Despite the epidemiological significance, older adults have been underrepresented in prospective trials, which hampers the applicability of existing results to clinical practice. Nevertheless, growing evidence suggests benefits of treating older patients according to their biological and not chronological age. In recurrent and/or metastatic SCCHN, treatment goals aim primarily at symptom palliation and maintaining a good quality of life. Most patients do not qualify for surgery or irradiation and are thus considered for a systemic approach or supportive care only. Currently, the platinum (cisplatin or carboplatin)/5-fluorouracil/cetuximab (EXTREME) regimen is the approved first-line systemic treatment for fit patients. Retrospective data indicate that older adults treated with chemotherapy yield outcomes comparable to their younger counterparts, albeit at the cost of increased toxicity. Taken together, fit elderly patients can be treated according to the EXTREME protocol but the exact role of targeted agents in this subgroup remains to be defined.

Citovat

SZTURZ, Petr a Jan B. VERMORKEN. Treatment in the Elderly. In Jan B. Vermorken, Volker Budach, C. René Leemans, Jean-Pascal Machiels, Piero Nicolai, Brian O'Sullivan. Critical Issues in Head and Neck Oncology. Switzerland: Springer International Publishing, 2017, s. 251-261. ISBN 978-3-319-42907-6. Dostupné z: https://dx.doi.org/10.1007/978-3-319-42909-0_16.

@inbook{1367416,
   author = {Szturz, Petr and Vermorken, Jan B.},
   address = {Switzerland},
   booktitle = {Critical Issues in Head and Neck Oncology},
   doi = {http://dx.doi.org/10.1007/978-3-319-42909-0_16},
   editor = {Jan B. Vermorken, Volker Budach, C. René Leemans, Jean-Pascal Machiels, Piero Nicolai, Brian O'Sullivan},
   keywords = {Biological age; Comorbidities; Functional status; Comprehensive geriatric assessment; Screening; Chemotherapy; Epidermal growth factor receptor inhibitor},
   howpublished = {tištěná verze "print"},
   language = {eng},
   location = {Switzerland},
   isbn = {978-3-319-42907-6},
   pages = {251-261},
   publisher = {Springer International Publishing},
   title = {Treatment in the Elderly},
   year = {2017}
}

TY  - CHAP
ID  - 1367416
AU  - Szturz, Petr - Vermorken, Jan B.
PY  - 2017
TI  - Treatment in the Elderly
VL  - Neuveden
PB  - Springer International Publishing
CY  - Switzerland
SN  - 9783319429076
KW  - Biological age
KW  - Comorbidities
KW  - Functional status
KW  - Comprehensive geriatric assessment
KW  - Screening
KW  - Chemotherapy
KW  - Epidermal growth factor receptor inhibitor
N2  - Older age is the major risk factor for cancer development and the steadily rising global cancer burden is directly linked to the growing number of the elderly population. In the United States, the proportion of squamous cell carcinoma of the head and neck (SCCHN) patients over 65 is estimated to increase from 54 % in 2010 up to 66 % by 2030. However, chronological age does not always correlate with biological parameters to reliably predict life expectancy, functional reserve and the risk of treatment side effects in an individual. Thus, geriatric assessment tools were developed to differentiate between the fit and frail senior persons and guide treatment decisions. According to the recommended two-step approach, geriatric screening tests (e.g. G8 or Flemish version of the Triage Risk Screening Tool) are used to select patients further requiring a full evaluation. A comprehensive geriatric assessment, which is otherwise time-consuming and not necessary in every case, evaluates functional status, comorbidities, medications, cognition, psychological status, nutrition and social support. Despite the epidemiological significance, older adults have been underrepresented in prospective trials, which hampers the applicability of existing results to clinical practice. Nevertheless, growing evidence suggests benefits of treating older patients according to their biological and not chronological age. In recurrent and/or metastatic SCCHN, treatment goals aim primarily at symptom palliation and maintaining a good quality of life. Most patients do not qualify for surgery or irradiation and are thus considered for a systemic approach or supportive care only. Currently, the platinum (cisplatin or carboplatin)/5-fluorouracil/cetuximab (EXTREME) regimen is the approved first-line systemic treatment for fit patients. Retrospective data indicate that older adults treated with chemotherapy yield outcomes comparable to their younger counterparts, albeit at the cost of increased toxicity. Taken together, fit elderly patients can be treated according to the EXTREME protocol but the exact role of targeted agents in this subgroup remains to be defined.
ER  -

SZTURZ, Petr a Jan B. VERMORKEN. Treatment in the Elderly. In Jan B. Vermorken, Volker Budach, C. René Leemans, Jean-Pascal Machiels, Piero Nicolai, Brian O'Sullivan. \textit{Critical Issues in Head and Neck Oncology}. Switzerland: Springer International Publishing, 2017, s.~251-261. ISBN~978-3-319-42907-6. Dostupné z: https://dx.doi.org/10.1007/978-3-319-42909-0\_{}16.

Podrobný výpis o publikaci